ST段抬高心肌梗死患者急性期循環(huán)單核細(xì)胞亞群改變與遠(yuǎn)期預(yù)后：血管緊張素轉(zhuǎn)換酶抑制劑與β受體阻滯劑的影響
發(fā)布時(shí)間：2018-12-16 01:08
【摘要】：目的:心肌梗死(myocardial infarction,MI)后,循環(huán)單核細(xì)胞被迅速激活并釋放大量蛋白水解酶和活性氧,是引起后續(xù)主要不良心血管事件(major adverse cardiovascular events,MACE)的原因之一。根據(jù)單核細(xì)胞表面CD標(biāo)志物的表達(dá)差異,人單核細(xì)胞分為三個(gè)亞群:經(jīng)典型(CD14++CD16-,Mon1)、中間型(CD14++CD16+,Mon2)和非經(jīng)典型(CD14+CD16++,Mon3)。此外,血小板被活化后與單核細(xì)胞結(jié)合形成單核細(xì)胞血小板聚集體(monocyte-platelet aggregates,MPA),參與多種病理生理過(guò)程。研究證實(shí),Mon2及Mon2 MPA是MI患者發(fā)生MACE的獨(dú)立危險(xiǎn)因素。基礎(chǔ)研究證實(shí),血管緊張素轉(zhuǎn)換酶抑制劑(angiotensin-converting enzyme inhibitor,ACEI)可以抑制MI小鼠單核細(xì)胞從骨髓和脾臟的動(dòng)員,進(jìn)而可改善MI誘發(fā)的單核細(xì)胞增多,因此有助于解釋ACEI的臨床收益。MI后,激活的交感-腎上腺素軸在單核細(xì)胞的骨髓動(dòng)員中發(fā)揮作用,提示β受體阻滯劑可能降低梗死區(qū)域的循環(huán)單核細(xì)胞數(shù)量。然而,目前尚缺乏ACEI和β受體阻滯劑對(duì)ST段抬高心肌梗死(ST-segment elevation myocardial infarction,STEMI)后單核細(xì)胞動(dòng)態(tài)變化影響的證據(jù),因此本研究旨在探討STEMI患者急性期ACEI及β受體阻滯劑的臨床應(yīng)用對(duì)循環(huán)單核細(xì)胞數(shù)量和遠(yuǎn)期預(yù)后的影響。方法:入選2012年12月至2013年5月(隊(duì)列1)及2015年1月至2015年12月(隊(duì)列2)發(fā)病后24小時(shí)內(nèi)就診于武警后勤學(xué)院附屬醫(yī)院(平津醫(yī)院)心臟中心接受急診經(jīng)皮冠狀動(dòng)脈介入治療(percutaneous coronary intervention,PCI)并行外周血單核細(xì)胞亞群流式分析的STEMI患者。STEMI患者發(fā)病24小時(shí)內(nèi),在無(wú)禁忌的情況下,均常規(guī)口服應(yīng)用ACEI及β受體阻滯劑。隊(duì)列1患者分R%于入院即刻、第2、3、5及7天抽取外周血進(jìn)行單核細(xì)胞亞群流式分析。隊(duì)列2患者于入院第2天抽取外周血進(jìn)行單核細(xì)胞亞群流式分析。隨訪患者3年內(nèi)MACE的發(fā)生情況。計(jì)算隊(duì)列1中每位STEMI患者單核細(xì)胞亞群軌跡的曲線下面積(Area Under Curve,AUC)和單核細(xì)胞計(jì)數(shù)的均數(shù)(average,Avg)作為各單核細(xì)胞亞群在整個(gè)急性期變化趨勢(shì)的評(píng)價(jià)指標(biāo)。結(jié)果:(1)隊(duì)列1中收錄了STEMI患者共96例。隊(duì)列2中收錄121例�？傃芯筷�(duì)列中:本研究最終納入217例STEMI患者。3年的隨訪中共46例患者發(fā)生MACE,其中心源性死亡10例、非致死性缺血性卒中3例、再發(fā)MI 3例、心力衰竭15例、需再次行急診或擇期血運(yùn)重建15例。(2)隊(duì)列1:入院24小時(shí)內(nèi)應(yīng)用ACEI患者的Mon1 Avg、Mon1 MPA Avg、Mon2 Avg、Mon2 MPA Avg水平均低于入院期間未應(yīng)用ACEI及入院24小時(shí)后應(yīng)用ACEI患者(all P0.05)。入院24小時(shí)內(nèi)應(yīng)用β受體阻滯劑患者急性期各單核細(xì)胞亞群均數(shù)及亞群相關(guān)MPA均數(shù)顯著低于入院期間未用β受體阻滯劑及入院24小時(shí)后應(yīng)用β受體阻滯劑患者(all P0.05)。(3)隊(duì)列1:與住院期間未應(yīng)用ACEI及入院24小時(shí)后應(yīng)用ACEI患者相比,入院24小時(shí)內(nèi)應(yīng)用ACEI患者M(jìn)on2 AUC更低(all P0.05)。與住院期間未應(yīng)用β受體阻滯劑患者相比,入院24小時(shí)內(nèi)應(yīng)用β受體阻滯劑患者急性期的各單核細(xì)胞亞群AUC及亞群相關(guān)MPA AUC水平更低(all P0.05)。(4)總研究隊(duì)列:與入院24小時(shí)內(nèi)應(yīng)用ACEI患者相比,住院期間未應(yīng)用ACEI及入院24小時(shí)后應(yīng)用ACEI患者的Mon2計(jì)數(shù)水平均更高(all P0.05)。與入院24小時(shí)內(nèi)應(yīng)用β受體阻滯劑患者相比,住院期間未應(yīng)用β受體阻滯劑及入院24小時(shí)后應(yīng)用β受體阻滯劑患者的Mon2計(jì)數(shù)值均更高(all P0.05)。(5)ROC曲線分析:隊(duì)列1中及總研究隊(duì)列中,Mon2計(jì)數(shù)的AUC分別是0.647(95%CI:0.521-0.773,P=0.024)及0.734(95%CI:0.655-0.814,P0.001),Mon2計(jì)數(shù)對(duì)MACE事件發(fā)生的判別能力均具有臨床意義,提示Mon2計(jì)數(shù)是判別STEMI患者是否發(fā)生3年MACE較好的預(yù)測(cè)因子。(6)COX回歸分析:總研究隊(duì)列中,根據(jù)住院期間用藥情況將STEMI患者分為四組,并用性別、BMI、門(mén)球時(shí)間、吸煙史、高血壓史和糖尿病史等傳統(tǒng)心血管疾病危險(xiǎn)因素進(jìn)行校正,與ACEI ANDβ-B組相比,None組患者發(fā)生MACE的風(fēng)險(xiǎn)增加了約1.2倍(HR 2.174,95%CI:1.014-4.794,0.045)。結(jié)論:本研究進(jìn)一步證實(shí),Mon2是影響STEMI患者3年MACE的獨(dú)立危險(xiǎn)因素;STEMI急性期患者早期應(yīng)用ACIE及β受體阻滯劑可明顯降低循環(huán)Mon2水平,并減少M(fèi)ACE的發(fā)生,改善預(yù)后。
[Abstract]:Objective: After myocardial infarction (MI), circulating mononuclear cells are rapidly activated and release a large amount of proteolytic enzyme and active oxygen, which is one of the causes of follow-up major adverse cardiovascular events (MACE). On the basis of the difference in the expression of CD markers on the surface of monocytes, human monocytes were divided into three subpopulations: typical (CD14 + + CD16-, Mon1), intermediate (CD14 + + CD16 +, Mon2), and non-typical (CD14 + CD16 + +, Mon3). In addition, the platelet is activated to form a monocyte-platelet aggregate (MPA) in combination with the monocytes to participate in a variety of pathophysiological processes. The study confirmed that Mon2 and Mon2 MPA were independent risk factors for MACE in MI patients. The basic study confirmed that the angiotensin-converting enzyme inhibitor (ACEI) can inhibit the mobilization of the mononuclear cells of the MI mice from the bone marrow and the spleen, and further improve the number of mononuclear cells induced by the MI, thus contributing to the interpretation of the clinical benefit of the ACEI. After MI, the activated sympathetic-epinephrine axis plays a role in the bone marrow mobilization of the monocytes, suggesting that the androgen receptor blocker may reduce the number of circulating monocytes in the infarct zone. However, there is a lack of evidence of the effects of ACEI and platelet receptor blockers on the dynamic changes of monocytes after ST-segment elevation myocardial infarction (STEMI), The purpose of this study is to study the effect of the clinical application of ACEI and VEGF in the acute phase of STEMI on the number of circulating monocytes and long-term prognosis. Methods: From December 2012 to May 2013 (Cohort 1) and from January 2015 to December 2015 (Cohort 2), the heart center of the Affiliated Hospital of the Military Police Logistics Academy (Pingjin Hospital) received emergency percutaneous coronary intervention. PCI) patients with STEMI in parallel peripheral blood monocyte subpopulation flow analysis. In the 24-hour period of onset of STEMI, ACEI and androgen receptor blockers were routinely administered orally in the absence of taboos. Peripheral blood was extracted from peripheral blood for subpopulation flow analysis at 2, 3, 5 and 7 days in Cohort 1. The patients with Cohort 2 were subjected to subpopulation-flow analysis of the peripheral blood on the second day of admission. The occurrence of MACE within 3 years of follow-up. The mean (average, Avg) of the subpopulation trajectory of the monocyte subpopulation in each STEMI patient in Cohort 1 was calculated as an evaluation index for each of the monocyte subpopulations in the entire acute phase. Results: (1) There were 96 patients with STEMI in Cohort 1. 121 cases were included in Cohort 2. In the total study cohort, 217 patients with STEMI were included in this study. In the 3-year follow-up, there were 46 patients with MACE, including 10 cases of cardiac death, 3 non-fatal ischemic stroke, 3 cases of MI, 15 cases of heart failure, and 15 cases of emergency or elective revascularisation. (2) Cohort 1: The level of Mon1 Avg, Mon1 MPA Avg, Mon2Ag, and Mon2 MPA Avg in patients with ACEI within 24 hours of admission was lower than that of ACEI and ACEI after 24 hours of admission (all P0.05). The mean number of sub-group and subgroup-related MPA in the acute stage of the patients who were admitted for 24 hours of admission was significantly lower than that of the patients who did not use the androgen receptor blocker and after 24 hours of admission (all P0.05). (3) Cohort 1: Compared with the patients who did not use ACEI during the hospitalization and after 24 hours of admission, the AUC of the Mon2 AUC was lower in the patients admitted to the hospital for 24 hours (all P0.05). The AUC and subgroup-related MPA AUC levels were lower in the acute phase of the patients admitted to the hospital for 24 hours compared to those who did not apply the androgen receptor blocker (all P0.05). (4) The total study cohort: compared with the patients who received ACEI within 24 hours of admission, the level of Mon2 in the patients who had not applied ACEI and ACEI after 24 hours of admission was higher (all P0.05). The number of Mon2 in the patients who did not use the antigen-receptor blocker during the hospitalization and after 24 hours of admission was higher (all P0.05) compared to the patients who were admitted to the hospital for 24 hours. (5) ROC curve analysis: in Cohort 1 and in the total study cohort, the AUC of the Mon2 counts was 0.647 (95% CI: 0.521-0.773, P = 0.024) and 0.734 (95% CI: 0.655-0.814, P0.001), and the ability of the Mon2 to count on the MACE event was clinically significant. It is suggested that the Mon2 count is a good predictor of whether the patients with STEMI have a 3-year MACE. (6) COX regression analysis: in the total study cohort, the STEMI patients were divided into four groups according to the medication during the hospitalization, and the risk factors of the traditional cardiovascular diseases such as sex, BMI, door ball time, smoking history, history of hypertension and the history of diabetes were corrected, compared with the ACEI AND A-B group, The risk of MACE in the None group increased by about 1. 2-fold (HR 2.174, 95% CI: 1,014-4.794, 0.045). Conclusion: The study further confirmed that Mon2 is an independent risk factor for the 3-year MACE in patients with STEMI. In the early stage of STEMI, the early application of ACIE and platelet receptor blockers can significantly reduce the level of circulating Mon2 and reduce the occurrence of MACE and improve the prognosis.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R542.22
本文編號(hào)：2381599
[Abstract]:Objective: After myocardial infarction (MI), circulating mononuclear cells are rapidly activated and release a large amount of proteolytic enzyme and active oxygen, which is one of the causes of follow-up major adverse cardiovascular events (MACE). On the basis of the difference in the expression of CD markers on the surface of monocytes, human monocytes were divided into three subpopulations: typical (CD14 + + CD16-, Mon1), intermediate (CD14 + + CD16 +, Mon2), and non-typical (CD14 + CD16 + +, Mon3). In addition, the platelet is activated to form a monocyte-platelet aggregate (MPA) in combination with the monocytes to participate in a variety of pathophysiological processes. The study confirmed that Mon2 and Mon2 MPA were independent risk factors for MACE in MI patients. The basic study confirmed that the angiotensin-converting enzyme inhibitor (ACEI) can inhibit the mobilization of the mononuclear cells of the MI mice from the bone marrow and the spleen, and further improve the number of mononuclear cells induced by the MI, thus contributing to the interpretation of the clinical benefit of the ACEI. After MI, the activated sympathetic-epinephrine axis plays a role in the bone marrow mobilization of the monocytes, suggesting that the androgen receptor blocker may reduce the number of circulating monocytes in the infarct zone. However, there is a lack of evidence of the effects of ACEI and platelet receptor blockers on the dynamic changes of monocytes after ST-segment elevation myocardial infarction (STEMI), The purpose of this study is to study the effect of the clinical application of ACEI and VEGF in the acute phase of STEMI on the number of circulating monocytes and long-term prognosis. Methods: From December 2012 to May 2013 (Cohort 1) and from January 2015 to December 2015 (Cohort 2), the heart center of the Affiliated Hospital of the Military Police Logistics Academy (Pingjin Hospital) received emergency percutaneous coronary intervention. PCI) patients with STEMI in parallel peripheral blood monocyte subpopulation flow analysis. In the 24-hour period of onset of STEMI, ACEI and androgen receptor blockers were routinely administered orally in the absence of taboos. Peripheral blood was extracted from peripheral blood for subpopulation flow analysis at 2, 3, 5 and 7 days in Cohort 1. The patients with Cohort 2 were subjected to subpopulation-flow analysis of the peripheral blood on the second day of admission. The occurrence of MACE within 3 years of follow-up. The mean (average, Avg) of the subpopulation trajectory of the monocyte subpopulation in each STEMI patient in Cohort 1 was calculated as an evaluation index for each of the monocyte subpopulations in the entire acute phase. Results: (1) There were 96 patients with STEMI in Cohort 1. 121 cases were included in Cohort 2. In the total study cohort, 217 patients with STEMI were included in this study. In the 3-year follow-up, there were 46 patients with MACE, including 10 cases of cardiac death, 3 non-fatal ischemic stroke, 3 cases of MI, 15 cases of heart failure, and 15 cases of emergency or elective revascularisation. (2) Cohort 1: The level of Mon1 Avg, Mon1 MPA Avg, Mon2Ag, and Mon2 MPA Avg in patients with ACEI within 24 hours of admission was lower than that of ACEI and ACEI after 24 hours of admission (all P0.05). The mean number of sub-group and subgroup-related MPA in the acute stage of the patients who were admitted for 24 hours of admission was significantly lower than that of the patients who did not use the androgen receptor blocker and after 24 hours of admission (all P0.05). (3) Cohort 1: Compared with the patients who did not use ACEI during the hospitalization and after 24 hours of admission, the AUC of the Mon2 AUC was lower in the patients admitted to the hospital for 24 hours (all P0.05). The AUC and subgroup-related MPA AUC levels were lower in the acute phase of the patients admitted to the hospital for 24 hours compared to those who did not apply the androgen receptor blocker (all P0.05). (4) The total study cohort: compared with the patients who received ACEI within 24 hours of admission, the level of Mon2 in the patients who had not applied ACEI and ACEI after 24 hours of admission was higher (all P0.05). The number of Mon2 in the patients who did not use the antigen-receptor blocker during the hospitalization and after 24 hours of admission was higher (all P0.05) compared to the patients who were admitted to the hospital for 24 hours. (5) ROC curve analysis: in Cohort 1 and in the total study cohort, the AUC of the Mon2 counts was 0.647 (95% CI: 0.521-0.773, P = 0.024) and 0.734 (95% CI: 0.655-0.814, P0.001), and the ability of the Mon2 to count on the MACE event was clinically significant. It is suggested that the Mon2 count is a good predictor of whether the patients with STEMI have a 3-year MACE. (6) COX regression analysis: in the total study cohort, the STEMI patients were divided into four groups according to the medication during the hospitalization, and the risk factors of the traditional cardiovascular diseases such as sex, BMI, door ball time, smoking history, history of hypertension and the history of diabetes were corrected, compared with the ACEI AND A-B group, The risk of MACE in the None group increased by about 1. 2-fold (HR 2.174, 95% CI: 1,014-4.794, 0.045). Conclusion: The study further confirmed that Mon2 is an independent risk factor for the 3-year MACE in patients with STEMI. In the early stage of STEMI, the early application of ACIE and platelet receptor blockers can significantly reduce the level of circulating Mon2 and reduce the occurrence of MACE and improve the prognosis.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R542.22
【參考文獻(xiàn)】
相關(guān)期刊論文 前6條
1 陳偉偉;高潤(rùn)霖;劉力生;朱曼璐;王文;王擁軍;吳兆蘇;李惠君;顧東風(fēng);楊躍進(jìn);鄭哲;蔣立新;胡盛壽;;《中國(guó)心血管病報(bào)告2015》概要[J];中國(guó)循環(huán)雜志;2016年06期
2 陳紀(jì)言;傅國(guó)勝;傅向華;葛均波;高煒;韓雅玲;霍勇;賈紹斌;李擁軍;喬樹(shù)賓;沈衛(wèi)峰;王建安;周玉杰;;血管緊張素轉(zhuǎn)換酶抑制劑在冠心病患者中應(yīng)用中國(guó)專家共識(shí)[J];中國(guó)循環(huán)雜志;2016年05期
3 高曉津;楊進(jìn)剛;楊躍進(jìn);許海燕;吳元;李衛(wèi);王揚(yáng);唐欣然;孫毅;喬國(guó)芳;宋雷;伏蕊;孫慧;嚴(yán)欣欣;董秋婷;張璇;葉蘊(yùn)青;金辰;;中國(guó)急性心肌梗死患者心血管危險(xiǎn)因素分析[J];中國(guó)循環(huán)雜志;2015年03期
4 陳韻岱;;β受體阻滯劑在冠狀動(dòng)脈粥樣硬化性心臟病治療中的應(yīng)用[J];中華高血壓雜志;2013年10期
5 楊國(guó)紅;盧芮伊;孫海英;張玲;姬文婕;周欣;石蕊;姜鐵民;李玉明;;四色流式分析冠心病患者外周血單核細(xì)胞亞群及單核細(xì)胞-血小板聚集體的變化[J];臨床心血管病雜志;2013年01期
6 張海波;張丹;李靜;李希;馮芳;劉佳敏;高巖;烏漢畢力格;葛蕾;龐鑫;LANDRAY Martin;ARMITAGE Jane;蔣立新;;β受體阻滯劑在中國(guó)高危冠心病患者中的應(yīng)用現(xiàn)狀調(diào)查[J];臨床心血管病雜志;2011年06期
，本文編號(hào)：2381599
本文鏈接：http://sikaile.net/yixuelunwen/xxg/2381599.html
最近更新
教材專著
